TY - JOUR
T1 - Expression of the thymidine phosphorylase gene in epithelial ovarian cancer
AU - Hata, K.
AU - Kamikawa, T.
AU - Arao, S.
AU - Tashiro, H.
AU - Katabuchi, H.
AU - Okamura, H.
AU - Fujiwaki, R.
AU - Miyazaki, K.
AU - Fukumoto, M.
N1 - Funding Information:
The work of KH is supported by a grant from Shimane Medical University Education and Research Foundation.
PY - 1999
Y1 - 1999
N2 - Thymidine phosphorylase (TP) is associated with angiogenesis and the progression of solid tumours. High intracellular levels of this enzyme indicate increased chemosensitivity to pyrimidine antimetabolites. TP gene expression in 56 cases of epithelial ovarian cancer (27 of serous, 10 mucinous, 12 endometrioid, five clear cell and two undifferentiated) were analysed by polymerase chain reaction of RNA after reverse transcription. These included eight of low malignant potential. Twenty were stage I, four stage II, 27 stage III and five stage IV. The level of TP gene expression was presented by the relative yield of the TP gene to the β2-microglobulin gene. TP gene expression ranged from 0.19 to 5.38 (median 0.93). The value of TP gene expression in stage III-IV was significantly higher than that of TP gene expression in stage I-II (P = 0.0005). Histological grade significantly associated with TP gene expression (P = 0.008), but histological subtype did not (P = 0.166). A follow-up study of 34 cases after complete resection of the primary tumours by surgical operation was performed. TP gene expression of the cases with recurrence showed significantly higher levels compared to cases without recurrence (P = 0.049). Survival data were available for 47 of the 56 patients. The prognosis of the patients with high TP gene expression (equal to, or greater than, median) was to be significantly worse than patients with low TP gene expression (less than median) (P = 0.021). The TP gene expression level may play one of the key roles in the biology of ovarian epithelial cancer and define a more aggressive tumour phenotype. A new therapeutic intervention mediated by TP protein activity is anticipated.
AB - Thymidine phosphorylase (TP) is associated with angiogenesis and the progression of solid tumours. High intracellular levels of this enzyme indicate increased chemosensitivity to pyrimidine antimetabolites. TP gene expression in 56 cases of epithelial ovarian cancer (27 of serous, 10 mucinous, 12 endometrioid, five clear cell and two undifferentiated) were analysed by polymerase chain reaction of RNA after reverse transcription. These included eight of low malignant potential. Twenty were stage I, four stage II, 27 stage III and five stage IV. The level of TP gene expression was presented by the relative yield of the TP gene to the β2-microglobulin gene. TP gene expression ranged from 0.19 to 5.38 (median 0.93). The value of TP gene expression in stage III-IV was significantly higher than that of TP gene expression in stage I-II (P = 0.0005). Histological grade significantly associated with TP gene expression (P = 0.008), but histological subtype did not (P = 0.166). A follow-up study of 34 cases after complete resection of the primary tumours by surgical operation was performed. TP gene expression of the cases with recurrence showed significantly higher levels compared to cases without recurrence (P = 0.049). Survival data were available for 47 of the 56 patients. The prognosis of the patients with high TP gene expression (equal to, or greater than, median) was to be significantly worse than patients with low TP gene expression (less than median) (P = 0.021). The TP gene expression level may play one of the key roles in the biology of ovarian epithelial cancer and define a more aggressive tumour phenotype. A new therapeutic intervention mediated by TP protein activity is anticipated.
KW - Epithelial ovarian cancer
KW - Gene expression
KW - Reverse transcriptase polymerase chain reaction
KW - Thymidine phosphorylase
UR - http://www.scopus.com/inward/record.url?scp=0033063734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033063734&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6690294
DO - 10.1038/sj.bjc.6690294
M3 - Article
C2 - 10206303
AN - SCOPUS:0033063734
VL - 79
SP - 1848
EP - 1854
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 11-12
ER -